Insitro stock
Private-market facts for current and former Insitro employees researching their stock.
Overview
Machine learning-driven drug discovery company integrating high-content biological data with ML to identify novel therapeutic targets and drugs.
Selling Insitro shares
Why shareholders consider selling
Shareholders in Insitro may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Insitro does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Insitro stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Insitro shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Insitro shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round and its reported $1B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Insitro shareholders
Exploring equity in Insitro often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Insitro most recently raised a Series C round in March 2022. The company was valued at $1B. Total funding raised to date is approximately $643M.
Lead investors in this round include Andreessen Horowitz and ARCH Venture Partners.
Founders & company background
Insitro was founded in 2018 by Daphne Koller and is headquartered in South San Francisco, CA.
Investors
Industry
Similar private companies
Latest Insitro news
Frequently asked questions
- Is Insitro still a private company?
- Yes, Insitro is currently a private company.
- What is Insitro's latest funding round?
- Insitro's most recent known round is Series C, raised in March 2022.
- What is Insitro's valuation?
- Insitro's latest reported valuation is $1B.
- Who are the investors in Insitro?
- Notable investors include Andreessen Horowitz, ARCH Venture Partners, Foresite Capital, GV (Google Ventures), T. Rowe Price.
- Can I sell my Insitro stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Insitro stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Insitro data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.